Skip To Main Content
Ravi B. Patel on Muck Rack

Ravi B. Patel

As seen in: Color Research & Application, Wiley, Wiley Online Library, JAMA (The Journal of the American Medical Association), JAMA Cardiology, Medscape, JACC (Journal of the American College of Cardiology), The Journal of Immunology, The American Journal of Medicine, The American Journal of Cardiology and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ravi B.

Contact Ravi B., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Validated Stability‐Indicating RP‐HPLC Method for Nirmatrelvir in Self‐Emulsifying Drug Delivery Systems: Formulation Characterization and Permeability Enhancement

|
By Ravi B. Patel, Ritu Sharma Verified, Dignesh Khunt, Binit Patel
| Wiley Online Library Verified
Conflicts of Interest The authors declare no conflicts of interest. Supporting Information References 1, , , , , and , “Nirmatrelvir and COVID-19: Development, Pharmacokinetics, Clinical Efficacy, Resistance, Relapse, and Pharmacoeconomics,” International Journal of Antimicrobial Agents 61 (2023): 106708, https://doi.org/10.1016/j.ijantimicag.2022.106708.
Open in Who Shared Issue with article?

A simplified approach for diagnosing heart failure with preserved ejection fraction by assessing the left atrium and natriuretic peptides

|
By Jerremy Weerts, Arantxa Barandiarán Aizpurua, Ravi B. Patel, CIBERCV Badalona Spain
| Wiley Online Library Verified
Introduction Heart failure (HF) with preserved ejection fraction (HFpEF) is a diagnostically challenging clinical syndrome with rising prevalence, while many patients are unrecognized.1 Facilitating an easier HFpEF diagnosis is essential.
Open in Who Shared Issue with article?

Cardiac Myosin Inhibition in Heart Failure With Normal and Supranormal Ejection Fraction

|
By Sanjiv Shah, Bristol Myers Squibb, New jersey, Ravi B. Patel
| JAMA Cardiology
Key Points Question What effect does the cardiac myosin inhibitor mavacamten have on cardiac biomarkers in patients with heart failure with preserved ejection fraction (HFpEF) and left ventricular ejection fraction (LVEF) of 60% or greater, and is mavacamten safe in these patients?
Open in Who Shared Issue with article?
See all 43 articles